glp-1 for diabetes type 2 receptor agonists are increasingly used to treat and obesity, and trials have shown reductions in cardiovascular risk and slowing of kidney failure. Adverse events are mostly gastrointestinal. Read The ABC's of GLP-1s: Benefits,

Individual outcomes in laboratory settings may vary and are not guaranteed

A shorter half-life necessitates more frequent administration to maintain a steady, therapeutic level

(2020) 2:e200026

Intravenous infusion of GLP-1 for 48 h in healthy human subjects increased muscle sympathetic nerve activity but had no effect on BP, norepinephrine plasma concentration, or the sympathetic/parasympathetic balance as estimated by the HR variability, suggesting that the increase in sympathetic drive is at least partially compensated by an increase in the parasympathetic activity [53]

The potential advent of an effective tau-directed disease-targeted therapies (DTTs) for AD may increase the volume of patients presenting earlier in the disease continuum, and increase complexity in workflow, infrastructure, treatment decision-making, treatment administration and monitoring, and patient tracking